Cargando…
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer
Intravesical BCG is active against non-muscle invasive bladder cancer (NMIBC), but bladder cancer will recur and even progress in a significant number of patients. To improve the response rate, N-803, an IL-15 superagonist was administered in combination with BCG. To evaluate the safety and efficacy...
Autores principales: | Rosser, Charles J., Tikhonenkov, Sergei, Nix, Jeffrey W., Chan, Owen T.M., Ianculescu, Irina, Reddy, Sandeep, Soon-Shiong, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096327/ https://www.ncbi.nlm.nih.gov/pubmed/33996264 http://dx.doi.org/10.1080/2162402X.2021.1912885 |
Ejemplares similares
-
VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951) -
Bacillus Calmette-Guerin (BCG) vaccine in Iran
por: Fallah, Fatemeh, et al.
Publicado: (2018) -
Bacillus Calmette-Guerin (BCG): the adroit vaccine
por: Adesanya, Oluwafolajimi A., et al.
Publicado: (2021) -
Disseminated Bacillus Calmette-Guérin (BCG) infections in infants with immunodeficiency
por: Al-Hammadi, Suleiman, et al.
Publicado: (2017) -
Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)